» Articles » PMID: 34882921

HPV16 E6/E7 Stabilize PGK1 Protein by Reducing Its Poly-ubiquitination in Cervical Cancer

Overview
Journal Cell Biol Int
Specialty Cell Biology
Date 2021 Dec 9
PMID 34882921
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to explore the expression profile, prognostic value, regulatory effect, and the underlying mechanism of dysregulation of phosphoglycerate kinase 1 (PGK1) in high-risk human papillomavirus (HPV)-positive cervical epithelial squamous cell carcinoma (CESC). Bioinformatic analysis was performed using the CESC subset of The Cancer Genome Atlas (TCGA)-Cervical Cancer (CESC) and normal cervix in The Genotype-Tissue Expression (GTEx) project. HPV-16 positive CaSki and SiHa cells were used as in vitro cell models. Results showed that compared to the normal cervix, CESC tissues had significantly higher expression of PGK1. CESC patients with the higher 50% expression of PGK1 had substantially shorter disease-specific survival (DSS), and progression-free survival (PFS) compared to the cases with the lower 50% expression of PGK1. PGK1 knockdown impaired, but PGK1 overexpression enhanced the proliferation, colony formation, aerobic glycolytic activities (lactate production, intracellular ATP levels, glucose uptake, and extracellular acidification rate), migration, and invasion of CaSki and SiHa cells. HPV-16 E6/E7 knockdown in CaSki and SiHa cells had limited influence on PGK1 transcription but significantly decreased the half-life of PGK1 protein. E6/E7 knockdown mediated PGK1 downregulation could be blocked by adding MG-132. PGK1 poly-ubiquitination was significantly enhanced after E6/E7 knockdown. In conclusion, this study showed that PGK1 expression might serve as a prognostic biomarker in cervical cancer. Its upregulation contributes to enhanced aerobic glycolysis, migration, and invasion of CESC cells. HPV16 E6/E7 stabilizes PGK1 protein by reducing its poly-ubiquitination.

Citing Articles

Overexpression of C1orf74 predicts poor outcome and promote cervical cancer progression.

Zhu H, Wang Y, Zhang Y, Tian Y, Liu D, Li X Heliyon. 2025; 10(24):e40966.

PMID: 39759315 PMC: 11699247. DOI: 10.1016/j.heliyon.2024.e40966.


HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor.

Peng Q, Wang L, Zuo L, Gao S, Jiang X, Han Y Cancer Gene Ther. 2023; 31(1):9-17.

PMID: 38102462 DOI: 10.1038/s41417-023-00682-3.


Cellular Retinoic Acid Binding Protein 2 (CRABP2), Up-regulated by HPV E6/E7, Leads to Aberrant Activation of the Integrin β1/FAK/ERK Signaling Pathway and Aggravates the Malignant Phenotypes of Cervical Cancer.

Liu J, Tang L, Chu W, Wei L Biochem Genet. 2023; 62(4):2686-2701.

PMID: 38001389 DOI: 10.1007/s10528-023-10568-6.


Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.

Ye J, Zheng L, He Y, Qi X MedComm (2020). 2023; 4(5):e368.

PMID: 37719443 PMC: 10501338. DOI: 10.1002/mco2.368.


N-Acetyl-L-Cysteine Reduces Cervical Carcinogenesis by Promoting Apoptosis.

Guo W, Jing W Drugs R D. 2023; 23(2):165-174.

PMID: 37266883 PMC: 10293158. DOI: 10.1007/s40268-023-00423-9.